Pharma’s newest nemesis? Nestlé works at the intersection of food and drugs to attack illnesses

Eric Palmer

If Big Pharma didn't already have enough to worry about, with patent cliffs, drug price investigations and reluctant payers, it now will have to face the onslaught of a large, well-funded company trying to create hybrid pharma and products company that would treat conditions from stomach disorders to Alzheimer's disease.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS